NASDAQ:AGEN - Agenus Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.95 0.00 (0.00 %) (As of 05/19/2019 04:00 PM ET)Previous Close$2.95Today's Range$2.88 - $2.9952-Week Range$1.54 - $3.88Volume975,394 shsAverage Volume872,601 shsMarket Capitalization$396.07 millionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Receive AGEN News and Ratings via Email Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AGEN Previous Symbol CUSIP00847G70 CIK1098972 Webagenusbio.com Phone781-674-4400Debt Debt-to-Equity RatioN/A Current Ratio1.70 Quick Ratio1.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$36.78 million Price / Sales10.77 Cash FlowN/A Price / Cash FlowN/A Book Value($0.89) per share Price / Book-3.31Profitability EPS (Most Recent Fiscal Year)($1.44) Net Income$-159,690,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-56.05%Miscellaneous Employees294 Outstanding Shares134,260,000Market Cap$396.07 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Agenus (NASDAQ:AGEN) Frequently Asked Questions What is Agenus' stock symbol? Agenus trades on the NASDAQ under the ticker symbol "AGEN." How were Agenus' earnings last quarter? Agenus Inc (NASDAQ:AGEN) announced its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.42. The biotechnology company had revenue of $8.61 million for the quarter, compared to analysts' expectations of $9.03 million. View Agenus' Earnings History. When is Agenus' next earnings date? Agenus is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Agenus. What price target have analysts set for AGEN? 1 equities research analysts have issued twelve-month target prices for Agenus' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Agenus' share price to reach $5.00 in the next year. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Agenus. What is the consensus analysts' recommendation for Agenus? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agenus. Has Agenus been receiving favorable news coverage? Headlines about AGEN stock have been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Agenus earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. Who are some of Agenus' key competitors? Some companies that are related to Agenus include Alector (ALEC), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Rubius Therapeutics (RUBY), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG), Autolus Therapeutics (AUTL), GENFIT S A/ADR (GNFT), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), MeiraGTx (MGTX) and Cellectis (CLLS). What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), Merrimack Pharmaceuticals (MACK), REDHILL BIOPHAR/S (RDHL), Opko Health (OPK), Gilead Sciences (gild), Energy Transfer LP Unit (ET), Novavax (NVAX), Synergy Pharmaceuticals (SGYP) and Celsion (CLSN). Who are Agenus' key executives? Agenus' management team includes the folowing people: Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)Dr. Jennifer Buell, Chief Operating OfficerDr. Alexander R. Duncan, CTO & Head of Research (Age 57)Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53) Who are Agenus' major shareholders? Agenus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.24%), Geode Capital Management LLC (0.88%), Northern Trust Corp (0.86%), Oxford Asset Management LLP (0.69%), Wells Fargo & Company MN (0.61%) and Morgan Stanley (0.60%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Garo H Armen and Karen Valentine. View Institutional Ownership Trends for Agenus. Which major investors are selling Agenus stock? AGEN stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Oxford Asset Management LLP, California State Teachers Retirement System, Zurcher Kantonalbank Zurich Cantonalbank and HighTower Advisors LLC. View Insider Buying and Selling for Agenus. Which major investors are buying Agenus stock? AGEN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Ingalls & Snyder LLC, Geode Capital Management LLC, Charles Schwab Investment Management Inc., Shell Asset Management Co., Northern Trust Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Agenus. How do I buy shares of Agenus? Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Agenus' stock price today? One share of AGEN stock can currently be purchased for approximately $2.95. How big of a company is Agenus? Agenus has a market capitalization of $396.07 million and generates $36.78 million in revenue each year. The biotechnology company earns $-159,690,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Agenus employs 294 workers across the globe. What is Agenus' official website? The official website for Agenus is http://agenusbio.com. How can I contact Agenus? Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected] MarketBeat Community Rating for Agenus (NASDAQ AGEN)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 371 (Vote Outperform)Underperform Votes: 279 (Vote Underperform)Total Votes: 650MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Understanding Relative Strength Index Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.